4FRONT-1 trial evaluates 4D-150 against aflibercept in wet AMD, focusing on visual acuity and treatment burden reduction over 52 weeks. 4D-150 offers sustained anti-VEGF delivery via a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback